FDA Extends Decision Date On Regenxbio's Gene Therapy Into Next Year

Regenxbio's Biologics License Application (BLA) for RGX-121, a treatment for Hunter syndrome (MPS II), saw its FDA review period extended from November 9, 2025, to February 8, 2026. This extension follows Regenxbio's submission of longer-term clinical data in response to an FDA request. Despite the delay, the FDA has raised no safety concerns and completed its inspection with no observations, indicating the submitted data is consistent with prior positive results. However, RGNX stock declined 7.46% on the news, reflecting market sensitivity to the delayed potential approval timeline.

Analysis

The U.S. FDA has extended its review timeline for Regenxbio's (RGNX) Biologics License Application for RGX-121 by three months to February 8, 2026, following the company's submission of requested longer-term clinical data. While this delay triggered a 7.46% decline in RGNX shares to $8.06, the underlying regulatory feedback appears constructive. Critically, the FDA has raised no safety-related concerns during the review and completed its pre-license inspection with no observations, mitigating two significant potential risks in the approval process. The submitted data, which will be detailed at the ICIEM in September 2025, is reported to be consistent with previously strong results from the Phase 1/2/3 CAMPSIITE trial. That trial met its primary endpoint with statistical significance, showing an 86% median reduction in a key biomarker of brain disease activity. The market's negative reaction reflects the deferred commercialization timeline and associated revenue, but the absence of fundamental safety or manufacturing issues suggests the fundamental case for approval remains intact, albeit postponed.

Key Decisions for Investors

• Investors should re-evaluate their valuation models to account for the three-month delay in the RGX-121 PDUFA date to February 8, 2026, which pushes back the potential revenue horizon.
• The 7.46% stock price decline presents a potential entry point for long-term investors, as the sell-off is tied to a timeline extension rather than a fundamental setback in safety or efficacy.
• Monitor the upcoming data presentation at the International Congress of Inborn Errors of Metabolism (ICIEM) in September 2025, as positive details could serve as a catalyst to reverse the current negative sentiment.
• Given that the FDA raised no safety concerns and the facility inspection was clean, the risk profile for an eventual approval appears lower than what the immediate stock reaction might suggest, warranting a closer look for those with a higher tolerance for timeline uncertainty.